These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33357778)

  • 1. Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances.
    Inoue Y; Tsuchimori K; Nakamura H
    J Pharmacol Sci; 2021 Jan; 145(1):42-51. PubMed ID: 33357778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.
    Harvey PD; Nakamura H; Miura S
    Neuropsychopharmacol Rep; 2020 Mar; 40(1):63-72. PubMed ID: 31788985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: a 1-year open-label trial.
    Ninomiya Y; Miyamoto S; Tenjin T; Ogino S; Miyake N; Kaneda Y; Sumiyoshi T; Yamaguchi N
    Psychiatry Clin Neurosci; 2014 Dec; 68(12):841-849. PubMed ID: 24835911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study.
    Iwata N; Ishigooka J; Kim WH; Yoon BH; Lin SK; Sulaiman AH; Cosca R; Wang L; Suchkov Y; Agarkov A; Watabe K; Matsui T; Sato T; Inoue Y; Higuchi T; Correll CU; Kane JM
    Schizophr Res; 2020 Jan; 215():408-415. PubMed ID: 31471246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance.
    Bo Q; Wang X; Liu X; Sang H; Xun Z; Zhang R; Yang X; Deng H; Li K; Chen J; Sun M; Zhao G; Liu X; Cai D; Zhan G; Li J; Li H; Wang G
    BMC Psychiatry; 2023 Feb; 23(1):115. PubMed ID: 36810039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study.
    Iwata N; Ishigooka J; Naoi I; Matsumoto M; Kanamori Y; Nakamura H; Higuchi T
    CNS Drugs; 2020 Jan; 34(1):103-116. PubMed ID: 31883082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial.
    Li H; Yao C; Shi J; Yang F; Qi S; Wang L; Zhang H; Li J; Wang C; Wang C; Liu C; Li L; Wang Q; Li K; Luo X; Gu N
    J Psychiatr Res; 2015 Oct; 69():102-9. PubMed ID: 26343601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study.
    Harvey PD; Nakamura H; Murasaki M
    Neuropsychopharmacol Rep; 2019 Sep; 39(3):173-182. PubMed ID: 31041855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blonanserin: a review of its use in the management of schizophrenia.
    Deeks ED; Keating GM
    CNS Drugs; 2010 Jan; 24(1):65-84. PubMed ID: 20030420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: A retrospective analysis.
    Tachibana M; Niitsu T; Watanabe M; Hashimoto T; Kanahara N; Ishikawa M; Iyo M
    Asian J Psychiatr; 2016 Dec; 24():28-32. PubMed ID: 27931902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
    Miura I; Shiga T; Katsumi A; Kanno-Nozaki K; Mashiko H; Niwa S; Yabe H
    Hum Psychopharmacol; 2014 Mar; 29(2):199-202. PubMed ID: 24590545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study.
    Saito T; Hyodo Y; Sakaguchi R; Nakamura H; Ishigooka J
    J Child Adolesc Psychopharmacol; 2022 Feb; 32(1):24-35. PubMed ID: 34612724
    [No Abstract]   [Full Text] [Related]  

  • 13. Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia.
    Nishibe H; Tateno A; Sakayori T; Yamamoto M; Kim W; Kakuyama H; Okubo Y
    Int J Neuropsychopharmacol; 2021 Feb; 24(2):108-117. PubMed ID: 32936897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study.
    Ishigooka J; Nakagome K; Ohmori T; Iwata N; Inada K; Iga JI; Kishi T; Fujita K; Kikuchi Y; Shichijo T; Tabuse H; Koretsune S; Terada H; Terada H; Kishimoto T; Tsutsumi Y; Kanda Y; Ohi K; Sekiyama K
    Psychiatry Clin Neurosci; 2022 Jan; 76(1):22-31. PubMed ID: 34626144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial.
    Pu C; Lei L; Yang F; Deng H; Sheng J; Liu Z; Hu S; Wang L; Wu B; Bo Q; Inoue Y; Yu X
    BMJ Open; 2022 Apr; 12(4):e054079. PubMed ID: 35443947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Blonanserin in the treatment of schizophrenia].
    Tenjin T; Miyamoto S
    Nihon Rinsho; 2013 Apr; 71(4):660-5. PubMed ID: 23678596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series.
    Kawabe K; Horiuchi F; Ueno S
    Clin Neuropharmacol; 2013; 36(6):239-41. PubMed ID: 24201238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.
    Saito T; Sugimoto S; Sakaguchi R; Nakamura H; Ishigooka J
    J Child Adolesc Psychopharmacol; 2022 Feb; 32(1):12-23. PubMed ID: 35133884
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Kishi T; Matsui Y; Matsuda Y; Katsuki A; Hori H; Yanagimoto H; Sanada K; Morita K; Yoshimura R; Shoji Y; Hagi K; Iwata N
    Pharmacopsychiatry; 2019 Feb; 52(2):52-62. PubMed ID: 29514360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year follow-up study of psychotic patients treated with blonanserin: a case series.
    Takahashi S; Suzuki M; Uchiyama M
    Asia Pac Psychiatry; 2013 Sep; 5(3):164-7. PubMed ID: 23857800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.